AR076388A1 - Procedimientos para mejorar la farmocinetica - Google Patents
Procedimientos para mejorar la farmocineticaInfo
- Publication number
- AR076388A1 AR076388A1 ARP100101352A ARP100101352A AR076388A1 AR 076388 A1 AR076388 A1 AR 076388A1 AR P100101352 A ARP100101352 A AR P100101352A AR P100101352 A ARP100101352 A AR P100101352A AR 076388 A1 AR076388 A1 AR 076388A1
- Authority
- AR
- Argentina
- Prior art keywords
- cytochrome
- inhibitor
- formula
- compound
- monooxygenase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
El objeto de la presente es el de elevar los niveles en sangre de un compuesto de la formula 1, mediante la co-administracion con un inhibidor del citocromo P450. Reivindicacion 1: Un procedimiento para incrementar la biodisponibilidad de un inhibidor de proteasa NS3/4A del virus de la hepatitis C, segun la formula 1, en un paciente, que comprende la co-administracion, al paciente, de un compuesto de la formula 1 y de un inhibidor de monooxigenasa del citocromo P450, en donde, el inhibidor de monooxigenasa, se encuentra presente en una cantidad suficiente como para levar los niveles en sangre de 1. Reivindicacion 2: Un procedimiento, segun la reivindicacion 1, en donde, el inhibidor de monooxigenasa del citocromo P450, es ritonavir. Reivindicacion 3: El procedimiento, segun la reivindicacion 2, en donde, el compuesto de la formula 1 y el ritonavir, se encuentran en formas separadas de dosificacion. Reivindicacion 15: Una composicion farmacéutica, que comprende un compuesto de la formula 1, o una base libre u otra sal farmacéuticamente aceptable de éste, y un inhibidor de monooxigenasa del citocromo P450 o una sal de éste farmacéuticamente aceptable, y por lo menos un excipiente, diluyente o vehículo (soporte), farmacéuticamente aceptable. El uso de R7227 y de un inhibidor de monooxigenasa del citocromo P450, en donde, la cantidad del inhibidor de monooxigenasa del citocromo P450, es suficiente, como para elevar los niveles en sangre del P7227, en comparacion con los niveles en sangre del R7227, en ausencia de un inhibidor de monooxigenasa del citocromo P450, para incrementar la biodisponibilidad de un inhibidor de NS3/4A-proteasa del virus de la hepatitis C, consistente en el R7227.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17272209P | 2009-04-25 | 2009-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076388A1 true AR076388A1 (es) | 2011-06-08 |
Family
ID=42236685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101352A AR076388A1 (es) | 2009-04-25 | 2010-04-23 | Procedimientos para mejorar la farmocinetica |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US20100272682A1 (es) |
| EP (1) | EP2421527B1 (es) |
| JP (1) | JP5523552B2 (es) |
| KR (1) | KR101471238B1 (es) |
| CN (2) | CN102413827A (es) |
| AR (1) | AR076388A1 (es) |
| AU (1) | AU2010240893B2 (es) |
| BR (1) | BRPI1015147B1 (es) |
| CA (1) | CA2758644C (es) |
| CL (1) | CL2011002643A1 (es) |
| CO (1) | CO6440593A2 (es) |
| CR (1) | CR20110551A (es) |
| DK (1) | DK2421527T3 (es) |
| EC (1) | ECSP11011420A (es) |
| ES (1) | ES2683736T3 (es) |
| HK (1) | HK1215858A1 (es) |
| HR (1) | HRP20181306T1 (es) |
| HU (1) | HUE040182T2 (es) |
| IL (1) | IL215620A (es) |
| LT (1) | LT2421527T (es) |
| MA (1) | MA33212B1 (es) |
| MX (2) | MX2011011105A (es) |
| MY (1) | MY169734A (es) |
| NZ (1) | NZ595917A (es) |
| PE (1) | PE20120638A1 (es) |
| PL (1) | PL2421527T3 (es) |
| PT (1) | PT2421527T (es) |
| RS (1) | RS57501B1 (es) |
| RU (1) | RU2591830C2 (es) |
| SG (1) | SG175328A1 (es) |
| SI (1) | SI2421527T1 (es) |
| TR (1) | TR201809600T4 (es) |
| TW (1) | TWI468160B (es) |
| UA (1) | UA103801C2 (es) |
| WO (1) | WO2010122087A1 (es) |
| ZA (1) | ZA201107421B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2011005695A0 (en) * | 2008-10-15 | 2011-06-30 | Intermune Inc | Therapeutic antiviral poptides. |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2455068A1 (en) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmaceutical composition for treating HCV infections |
| CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CA2863002A1 (en) | 2012-01-11 | 2013-07-18 | Abbvie Inc. | Processes for making hcv protease inhibitors |
| US20140024613A1 (en) * | 2012-06-27 | 2014-01-23 | Abbvie Inc. | Methods for Treating HCV |
| MX2015004411A (es) | 2012-10-08 | 2016-04-06 | Abbvie Inc | Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc). |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| HUE044606T2 (hu) * | 2014-05-01 | 2019-11-28 | Eiger Biopharmaceuticals Inc | A hepatitis delta vírusfertõzés kezelése |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| DK3285768T3 (da) | 2015-04-21 | 2021-01-25 | Eiger Biopharmaceuticals Inc | Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN117105928B (zh) * | 2023-08-22 | 2024-03-26 | 上海蓝木化工有限公司 | 一种蛋白酶抑制剂及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69332616T2 (de) | 1992-12-29 | 2003-11-06 | Abbott Laboratories, Abbott Park | Hemmer der retroviralen Protease |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| IL141438A0 (en) | 2000-02-23 | 2002-03-10 | Pfizer Prod Inc | Method of increasing the bioavailability and tissue penetration of azithromycin |
| CZ2003195A3 (cs) * | 2000-07-21 | 2003-04-16 | Schering Corporation | Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek |
| RS20050461A (en) | 2002-12-16 | 2007-08-03 | Boehringer Ingelheim International Gmbh., | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrt) with an inhibitor of cytochrome p450, such as protease inhibitors |
| PL1677827T3 (pl) * | 2003-10-27 | 2009-06-30 | Vertex Pharma | Połączenia do leczenia HCV |
| US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| US20120220520A1 (en) * | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
-
2010
- 2010-04-22 LT LTEP10714883.5T patent/LT2421527T/lt unknown
- 2010-04-22 RS RS20180898A patent/RS57501B1/sr unknown
- 2010-04-22 MA MA34273A patent/MA33212B1/fr unknown
- 2010-04-22 NZ NZ595917A patent/NZ595917A/en unknown
- 2010-04-22 RU RU2011142651/15A patent/RU2591830C2/ru active
- 2010-04-22 WO PCT/EP2010/055317 patent/WO2010122087A1/en active Application Filing
- 2010-04-22 UA UAA201113756A patent/UA103801C2/ru unknown
- 2010-04-22 PT PT107148835T patent/PT2421527T/pt unknown
- 2010-04-22 KR KR1020117027997A patent/KR101471238B1/ko active IP Right Grant
- 2010-04-22 BR BRPI1015147-8A patent/BRPI1015147B1/pt active IP Right Grant
- 2010-04-22 MX MX2011011105A patent/MX2011011105A/es active IP Right Grant
- 2010-04-22 SG SG2011077732A patent/SG175328A1/en unknown
- 2010-04-22 ES ES10714883.5T patent/ES2683736T3/es active Active
- 2010-04-22 TR TR2018/09600T patent/TR201809600T4/tr unknown
- 2010-04-22 MX MX2013013597A patent/MX351185B/es unknown
- 2010-04-22 PE PE2011001850A patent/PE20120638A1/es active IP Right Grant
- 2010-04-22 EP EP10714883.5A patent/EP2421527B1/en active Active
- 2010-04-22 CA CA2758644A patent/CA2758644C/en active Active
- 2010-04-22 HU HUE10714883A patent/HUE040182T2/hu unknown
- 2010-04-22 CN CN2010800181204A patent/CN102413827A/zh active Pending
- 2010-04-22 TW TW99112703A patent/TWI468160B/zh active
- 2010-04-22 JP JP2012506491A patent/JP5523552B2/ja active Active
- 2010-04-22 MY MYPI2011005073A patent/MY169734A/en unknown
- 2010-04-22 PL PL10714883T patent/PL2421527T3/pl unknown
- 2010-04-22 AU AU2010240893A patent/AU2010240893B2/en active Active
- 2010-04-22 DK DK10714883.5T patent/DK2421527T3/en active
- 2010-04-22 SI SI201031725T patent/SI2421527T1/sl unknown
- 2010-04-22 CN CN201510706536.XA patent/CN105233249A/zh active Pending
- 2010-04-23 AR ARP100101352A patent/AR076388A1/es not_active Application Discontinuation
- 2010-04-23 US US12/766,051 patent/US20100272682A1/en not_active Abandoned
-
2011
- 2011-10-06 IL IL215620A patent/IL215620A/en active IP Right Grant
- 2011-10-10 ZA ZA2011/07421A patent/ZA201107421B/en unknown
- 2011-10-12 CO CO11135691A patent/CO6440593A2/es active IP Right Grant
- 2011-10-19 CR CR20110551A patent/CR20110551A/es unknown
- 2011-10-24 CL CL2011002643A patent/CL2011002643A1/es unknown
- 2011-10-25 EC EC2011011420A patent/ECSP11011420A/es unknown
-
2016
- 2016-04-05 HK HK16103828.4A patent/HK1215858A1/zh unknown
-
2017
- 2017-01-12 US US15/404,398 patent/US20170119739A1/en not_active Abandoned
-
2018
- 2018-07-11 US US16/033,177 patent/US20180318267A1/en not_active Abandoned
- 2018-08-10 HR HRP20181306TT patent/HRP20181306T1/hr unknown
-
2020
- 2020-04-08 US US16/842,855 patent/US10918626B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076388A1 (es) | Procedimientos para mejorar la farmocinetica | |
| DOP2019000218A (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas | |
| CL2012000919A1 (es) | Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c. | |
| UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
| ECSP12011624A (es) | Composición Farmacéutica para un Inhibidor de Proteasa del Virus de la Hepatitis C. | |
| ECSP12012147A (es) | Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales | |
| UY30392A1 (es) | Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c | |
| CO6561788A2 (es) | Inhibidores del virus de la hepatitis c | |
| ECSP077648A (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| ECSP11010948A (es) | Inhibidores de las enzimas de proteína cinasa activadas por | |
| CL2008003384A1 (es) | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. | |
| CL2012001449A1 (es) | Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion. | |
| ECSP077649A (es) | Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| ECSP12012067A (es) | Inhibidores del virus de la hepatitis c | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| CL2012001230A1 (es) | Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c. | |
| CO6501153A2 (es) | Inhibidores macrociclicos de serina proteasa | |
| CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
| UY31215A1 (es) | Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia. | |
| AR089578A1 (es) | Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| UY30903A1 (es) | Nuevas sformas de sales de n-[2-(dietilamino)etil]-n-(2-{[2-(4-hidorxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoxi]propanamida, composiciones comprendiéndolas, procesos de preparacion y aplicaciones. | |
| CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
| CL2008003267A1 (es) | Compuestos derivados de macrociclos fusionados con pirrolidina, inhibidores de la serina proteasa ns3; composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la hepatitis c. | |
| ECSP13012791A (es) | Inhibidores de serina proteasa de hepatitis c a base de macrocíclicos de fenantridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |